Advertisement

Topics

Clinical collaboration set to evaluate combined treatment for cancer

09:38 EDT 1 Aug 2017 | EPM Magazine

A clinical collaboration between Bristol-Myers Squibb and Clovis Oncology has been announced, which will evaluate the combination of Opdivo (nivolumab) and Rubraca (rucaparib) in Phase II and III trials for multiple tumour types.

Original Article: Clinical collaboration set to evaluate combined treatment for cancer

NEXT ARTICLE

More From BioPortfolio on "Clinical collaboration set to evaluate combined treatment for cancer"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Story